Fairchild Semiconductor Intl, Inc. FCS
19.86 0.00 (+0.00%)
At closeJun 28, 2019, 6:07 PM EDT
19.84 Day range 19.88
12.95 52-week range 21.71
News
businesswire.com Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial…
businesswire.com NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales CAMBRIDGE, England--(BUSINESS WIRE)--FOR UK HEALTHCARE/TRADE MEDIA ONLY Sobi® UK today announced that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance…
gurufocus.com Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia [url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's
gurufocus.com Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with sever
businesswire.com People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that people in Germany who live with a rare metabolic condition called Familial Chylomicronaemia…
gurufocus.com Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia [url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of pl
gurufocus.com TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) [url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZAÂ (olezarsen) a
businesswire.com Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for…
gurufocus.com Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress [url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moder
prnewswire.com Esquire Bank Earns Multiple Honors at 2026 FCS Portfolio Awards JERICHO, N.Y., May 14, 2026 /PRNewswire/ -- Esquire Financial Holdings, Inc. (NASDAQ:ESQ) (the "Company"), the financial holding company for Esquire Bank, National Association ("Esquire Bank" or the…
businesswire.com Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO®…
businesswire.com Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA…
businesswire.com Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO®…
businesswire.com Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™…
businesswire.com Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a…
businesswire.com TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet…
businesswire.com TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
businesswire.com Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We'll Get There Soon campaign, initially launched for…
seekingalpha.com Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of…
businesswire.com Bowman Acquires Utility Services and Sustainability Solutions Firm FCS Group RESTON, Va.--(BUSINESS WIRE)--Bowman Consulting Group Ltd. (the “Company” or “Bowman”) (NASDAQ: BWMN), a national engineering services firm delivering infrastructure design solutions to customers who…
benzinga.com Top Percentage Gainers and Losers as of 10am 4/14/11(SVU, SIFY, JADE, WAVX, INVE, ABMD, TSTC, GFRE, FCS, ISTA)